Extracorporeal photopheresis for the treatment of early-stage mycosis fungoides.
Extracorporeal photopheresis (ECP) has been used for nearly 30 years in the treatment of cutaneous T-cell lymphoma. However, current clinical practice largely reserves ECP for patients with late-stage mycosis fungoides (MF) or Sézary syndrome or for those who are refractory to other therapies. We briefly describe a 48-year-old male who experienced long-term complete remission of his patch MF disease with ECP, and we suggest a role for ECP in the treatment of early-stage MF given evidence of its efficacy, safety, and tolerability.
School of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, Texas.|Department of Dermatology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1452, Pickens 411, Houston, Texas.
Daniel J
http://orcid.org/0000-0002-1610-5785
DJ
Lewis
Department of Dermatology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1452, Pickens 411, Houston, Texas.
Madeleine
M
Duvic
D006801:Humans; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000473:pathology / Q000628:therapy*; D017893:Photopheresis / Q000379:methods*; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
Mycosis fungoides; Sézary syndrome; early stage; extracorporeal photopheresis